纤溶因子,Fibrinolytic factors
1)Fibrinolytic factors纤溶因子
1.Fibrinolytic factors and its inhibitors in rabbit tissue extract;家兔组织浸液纤溶因子及其抑制物的实验研究
英文短句/例句

1.The Characteristic Research of Fibrinolytic Factors in Pcos;多囊卵巢综合征纤溶因子的特征研究
2.The Differential Diagnostic Value of Major Fibrinolytic Parameters in Pleural Fluid胸腔积液中纤溶因子的检测及其临床意义
3.Clinical and Experimental Study of Effect of Continuous Blood Purification on Thrombotic and Fibrinolytic Factors and Mechanism;连续性血液净化对凝血纤溶因子影响及其机制的临床与实验研究
4.In Silico Cloning of Component F-I-0 Gene of Earthworm Fibrinolytic Enzymes;蚯蚓纤溶酶F-I-0基因的电子克隆
5.Expression of Plasminogen Activator、Plasminogen Activator Inhibitor in Polycystic Ovary Syndrome纤溶酶原激活、抑制因子在PCOS卵巢中的表达
6.The Study on Relationship between the Expression of Plasminogen Activator, Plasminogen Activator Inhibitors and Invasion and Metastasis in Ovarian Carcinoma;纤溶酶原激活因子及其抑制因子与卵巢癌的浸润转移
7.The expression of plasminogen activator inhibitor 1 (PAI 1) gene in human astrocytomasG人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究
8.Treatment of Experimental Hepatic Fibrosis by Combination of Urokinase-type Plasminogen Activator and Hepatocyte Growth Factor Gene Delivery;尿激酶型纤溶酶原激活剂和肝细胞生长因子联合基因治疗实验性肝纤维化
9.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
10.Effects of caesarean section on neonate umbilical cord blood plasmin and immunologic factors选择性剖宫产对新生儿脐血纤溶酶活性及免疫因子的影响
11.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
12.Investigation of Soluble TNF-α Receptor to Silica Induced Pulmonary Fibrosis in Rats;肿瘤坏死因子-α可溶性受体对矽肺纤维化的干预研究
13.The Correlation between Plasma Level of Inflammatory Cytokines and Fibrinolytic Capacity in Patients with Acute Coronary Syndrome急性冠脉综合征患者纤溶活性与炎症因子的关系
14.Cloning and Expression of Urokinase Type Plasminogen Activator cDNA尿激酶型纤溶酶原激活因子cDNA的克隆与原核表达
15.Soluble Expression of Recombinant Human Fibroblast Growth Factor-8a in Escherichia coli重组人成纤维细胞生长因子-8a在大肠杆菌中的可溶性表达
16.Association of plasminogen activator inhibitor-1 gene promoter 4G/5G genotype polymorphism with gestational diabetes纤溶酶原激活物抑制因子1基因启动子区4G/5G多态性与妊娠糖尿病的相关性研究
17.The Changes of the Plasiminogen Activitor Inhibitor-1(PAI-1) in Patients with Coronary Heart Desease and It s Relationship to Clinical Factors;冠心病患者血浆纤溶酶原激活剂抑制因子(PAI-1)的变化及其相关因素的研究
18.Study of the Urokinase-type Plasminogen Activator Inhibited by Triplex-Forming Oligonucleotides in Rat Sertoli Cells;三链形成寡核苷酸对大鼠Sertoli细胞尿激酶型纤溶酶原激活因子的反基因研究
相关短句/例句

fibrinolytic regulator纤溶调节因子
3)Plasminogen activator纤溶酶原激活因子
1.Expressions of plasminogen activators and inhibitors in mice during reproductive cycle;小鼠生殖周期中纤溶酶原激活因子及抑制因子的表达
2.Plasminogen activators include urokinase type(uPA) and tissue type(tPA) plasminogen activator,which play a critical role in promoting proteolysis of extracellular matrix.纤溶酶原激活因子(PA)包括尿激酶型(uPA)及组织型(tPA),在诱发细胞外基质蛋白水解中起重要作用。
3.Researches on the mechanism of semen delayed liquefaction resulting from CP mainly focus on the proteolytic ferment,plasminogen activator,prostate acid phosphatase,tissue factor,lack of zinc,and pH.目前对CP所致精液延迟液化机制的研究主要集中在蛋白水解酶系、纤溶酶原激活因子系统和微量元素锌缺乏以及pH值改变等方面。
4)recombinant fibrinolytic enzyme重组蛇毒纤溶因子
1.Objective:Immobilizing rF Ⅱ,a recombinant fibrinolytic enzyme from agkistrodon acutus venom,to polyurethane to improve the surface antithrombogenicity.目的:通过聚氨酯表面偶联重组蛇毒纤溶因子rF Ⅱ来提高其纤溶活性。
5)plasminogen activator inhibitors1型纤溶酶原抑制因子
6)plasminogen activator尿型纤溶酶原激活因子
1.The relationship between the expression of plasminogen activator,plasminogen activator inhibitors and invasion and metastasis in ovarian carcinoma;尿型纤溶酶原激活因子及其1型抑制因子mRNA表达与卵巢癌临床病理及预后的关系
2.Objective:To explore the clinical-pathologic parameters on expression of plasminogen activator(uPA),plasminogen activator inhibitors(PAI-1) in ovarian cancer.目的:探讨卵巢恶性肿瘤组织中尿型纤溶酶原激活因子(uPA)及其1型抑制因子(PAI-1)表达的临床意义。
延伸阅读

冷不溶球蛋白 ,因子Ⅷ,人凝血因子Ⅷ浓缩剂药物名称:冷不溶球蛋白英文名:Globulinum Antihaemophiliae Humanum别名: 冻干人体血友病球蛋白;抗血友病球蛋白;冷不溶球蛋白 ,因子Ⅷ,人凝血因子Ⅷ浓缩剂外文名:Globulinum Antihaemophiliae Humanum 适应症: 本品适用于防治血友病甲(先天性凝血因数Ⅷ缺乏症)、获得性凝血因数Ⅷ缺乏症和血管性假血友病的补充疗法。对血友病乙(缺乏凝血因数Ⅳ)无效。 用量用法: 静注:通常每次每公斤体重5~10u,用25~30℃注射用水100ml溶解,于20分钟内输完。每隔12~24小时1次,连用3~5日即可。在出血量较大或大手术时,剂量可加大2~3倍,间隔时间可缩短,滴速60滴/min。输液器应有沪网装置。 注意事项: 1.大剂量输注时可出现肺水肿。 2.本制品应与受血者血型相同。 规格: 针剂:200u(相当于200ml血浆中所含的AHG)、另含纤维蛋白原0.1~0.2g。 类别:促凝血药